How to legally get Wegovy online in Florida

The Short Answer: Yes, With Some State Variations

In today’s digital-first healthcare landscape, many patients wonder if they can access popular GLP-1 weight loss medications like Wegovy, Ozempic, and Mounjaro through telehealth services. The answer is yes – these medications can legally be prescribed via telehealth appointments in all U.S. states, though some states have additional requirements that patients and providers must follow.

Unlike controlled substances (such as Adderall or certain pain medications), GLP-1 weight loss medications are not controlled substances under federal law. This means they’re not subject to the strict DEA Ryan Haight Act requirements that typically limit telehealth prescribing. However, state regulations and medical board guidelines vary considerably, which affects how telehealth weight loss care is delivered across the country.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Understanding GLP-1 Medications and Telehealth Prescribing

GLP-1 receptor agonists (like semaglutide and tirzepatide) have revolutionized weight management by mimicking gut hormones that regulate hunger and blood sugar. Originally developed for diabetes, these medications have proven remarkably effective for weight loss in clinical trials, with patients losing an average of 15-20% of their body weight in some studies.

The three main FDA-approved GLP-1 medications for weight management include:

• Wegovy (semaglutide 2.4mg): FDA-approved specifically for chronic weight management
• Ozempic (semaglutide 0.5-1mg): FDA-approved for Type 2 diabetes, often prescribed off-label for weight loss
• Mounjaro/Zepbound (tirzepatide): Approved for Type 2 diabetes and, as Zepbound, for weight management

Federal Telehealth Regulations

Under federal law, these medications can be prescribed via telehealth without requiring an initial in-person visit. Since GLP-1s are non-controlled medications, they aren’t subject to the Ryan Haight Act restrictions that apply to controlled substances.

As Dr. Jennifer Warren, Chief Medical Officer at Klarity Health explains: ‘GLP-1 medications have transformed obesity treatment, and telehealth has made these treatments accessible to patients who might otherwise face significant barriers to care. For non-controlled medications like Wegovy, federal law permits telehealth prescribing without the in-person requirements that apply to controlled substances.’

State-by-State Telehealth Rules for GLP-1 Medications

While federal law enables telehealth prescribing of GLP-1s, state regulations can impose additional requirements. Here’s how the landscape varies across states:

States Allowing Telehealth Prescribing Without In-Person Requirements

Several states permit telehealth providers to prescribe GLP-1 weight loss medications without requiring an initial in-person examination. These include:

• California: Fully permits telehealth prescribing with no in-person requirement
• Connecticut: No in-person mandate for weight loss medications
• Florida: Allows telehealth prescribing but requires follow-up every 3 months
• Illinois: No in-person requirement for GLP-1 medications
• New York: Fully embraces telehealth with no in-person mandate
• Pennsylvania: No specific in-person requirement for weight loss medications
• Washington: Pioneer in telehealth with no in-person requirement

States Requiring Initial In-Person Exams

Some states mandate an initial in-person examination before continuing treatment via telehealth:

• Arkansas: Requires an initial in-person examination
• Delaware: First exam must be conducted in-person
• Georgia: In-person exam required prior to telehealth prescribing
• Mississippi: Requires seeing patients in-person at least once
• New Jersey: Comprehensive in-person exam and labs required initially
• North Dakota: Initial in-person evaluation expected
• South Carolina: Must examine patient in-person first
• Texas: Generally expects an initial in-person exam
• Utah: Initial in-person exam encouraged
• Virginia: Physical exam and labs required initially

Why Do These Differences Exist?

These variations reflect different approaches to medical regulation. Some states prioritize expanding healthcare access through telehealth, while others maintain traditional requirements designed to ensure patient safety and appropriate care.

Medical boards in states with in-person requirements often cite concerns about proper baseline evaluations, the need for physical examinations to rule out contraindications, and ensuring patients meet clinical criteria for GLP-1 therapy.

Provider Qualifications and Prescribing Authority

Another important consideration is which healthcare providers can prescribe GLP-1 medications via telehealth:

• Physicians (MDs and DOs): Can prescribe in all states (when licensed in the patient’s state)
• Nurse Practitioners (NPs): Prescribing authority varies by state:
• Independent practice in states like Washington, California, New York
• Collaborative practice required in states like Texas, Florida, Pennsylvania
• Physician Assistants (PAs): Generally require physician supervision, with varying levels of autonomy by state

When using telehealth services like Klarity Health, patients may be matched with various types of qualified providers based on their state’s regulations. All providers are appropriately licensed and credentialed to practice in your state.

What to Expect During a Telehealth Consultation for GLP-1 Medications

A legitimate telehealth consultation for weight loss medications typically includes:

1. Pre-Appointment Screening

• Detailed medical history questionnaire
• Current medication list
• Height, weight, and BMI calculation
• Verification of identity and location (to ensure provider licensing compliance)

2. Video Consultation

• Discussion of weight history and previous weight loss attempts
• Review of medical history and potential contraindications
• Explanation of medication options, benefits, and potential side effects
• Assessment of whether you meet clinical criteria (typically BMI ≥30, or ≥27 with weight-related conditions)

3. Treatment Planning

• Personalized medication recommendations
• Lifestyle modifications (diet, exercise plan)
• Monitoring schedule and follow-up appointments
• Information about potential side effects and management strategies

4. Prescription and Follow-Up

• Electronic prescription sent to your local pharmacy
• Regular follow-up appointments (typically monthly at first, then every 2-3 months)
• Monitoring of weight loss progress and side effects
• Potential laboratory monitoring as needed

Red Flags to Watch For

Unfortunately, the popularity of GLP-1 medications has led to some questionable telehealth practices. Be wary of services that:

• Guarantee a prescription without a thorough evaluation
• Don’t require a video consultation with a licensed provider
• Sell compounded or overseas versions of semaglutide (FDA banned most compounded versions in 2025)
• Don’t schedule regular follow-ups
• Lack transparency about provider credentials
• Skip discussion of risks, side effects, and alternatives

Reputable telehealth providers like Klarity Health adhere to strict medical standards, require comprehensive evaluations, and provide ongoing care that matches in-person quality.

Insurance Coverage for Telehealth GLP-1 Prescriptions

Insurance coverage for GLP-1 medications varies significantly by insurer and plan. Some considerations:

• Many insurance plans cover Wegovy and similar medications for patients who meet specific BMI criteria and have obesity-related conditions
• Prior authorization is often required, documenting medical necessity
• Some plans may require documented failure of other weight loss methods
• Telehealth visits themselves are increasingly covered by insurance
• For patients without coverage, cash-pay options are available through various telehealth providers

Klarity Health works with patients to understand their coverage options and offers transparent pricing for both insurance-covered and cash-pay patients.

Patient Eligibility and Clinical Criteria

Despite growing accessibility, not everyone qualifies for GLP-1 weight loss medications. Typical clinical criteria include:

• BMI ≥30 (obesity), or BMI ≥27 with at least one weight-related health condition
• No personal or family history of medullary thyroid carcinoma or MEN2
• Not pregnant, breastfeeding, or planning pregnancy
• No history of pancreatitis or active gallbladder disease
• Commitment to lifestyle modifications alongside medication

Providers must screen for contraindications and ensure appropriate patient selection, regardless of whether care is delivered in-person or via telehealth.

The Future of Telehealth for Weight Management

The landscape of telehealth weight management continues to evolve. Looking ahead:

• Regulatory alignment: More states are likely to adopt flexible telehealth models as outcomes data demonstrates effectiveness
• Technology integration: Increased use of digital health tools for monitoring and support between appointments
• Medication access: Growing insurance coverage as long-term benefits of weight

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid